Immune-checkpoint inhibitors (ICIs) represent a major development in cancer therapy. The indications for these agents continue to expand across malignancies and disease settings. For years breast cancer (BC) has been considered immunologically quiescent compared with other tumor types. However, recent findings highlighted the immunogenicity of some BCs and paved the way for clinical trials of immunotherapy in BC that led to recent landmark approvals. As a drawback, the safety profile of ICIs is shaped by a specific spectrum of immune-related adverse events (irAEs) that can vary according to ICI class and tumor histology. This review will discuss the epidemiology of these adverse events, their kinetics, risk factors and the most important aspects in their management. A particular focus will be put on BC as the current landscape of immunotherapy for this disease is rapidly increasing the number of people treated with ICIs, thus susceptible to irAEs.
Managing side effects of immune checkpoint inhibitors in breast cancer / C. Criscitiello, C. Corti, G. Pravettoni, G. Curigliano. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 162(2021).
|Titolo:||Managing side effects of immune checkpoint inhibitors in breast cancer|
CRISCITIELLO, CARMEN (Primo)
PRAVETTONI, GABRIELLA (Penultimo)
CURIGLIANO, GIUSEPPE (Ultimo) [Conceptualization] (Corresponding)
|Parole Chiave:||adverse events; breast cancer; immune checkpoint inhibitors; immunotherapy; management|
|Settore Scientifico Disciplinare:||Settore MED/06 - Oncologia Medica|
|Data di pubblicazione:||2021|
|Data ahead of print / Data di stampa:||21-mag-2021|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.critrevonc.2021.103354|
|Appare nelle tipologie:||01 - Articolo su periodico|